<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01260753</url>
  </required_header>
  <id_info>
    <org_study_id>PPh/00071/10</org_study_id>
    <secondary_id>2010-021858-20</secondary_id>
    <nct_id>NCT01260753</nct_id>
  </id_info>
  <brief_title>Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge</brief_title>
  <official_title>Double Blind Randomised Placebo and Active Controlled, Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge to Allergic Patients Otherwise Healthy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Palau Pharma S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Palau Pharma S.A.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the activity of UR-63325 in a model of allergic
      rhinitis induced by nasal allergen challenge to known allergic rhinitis patients otherwise
      healthy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nasal and ocular symptoms scores after nasal allergen challenge</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory parameters measured from nasal exudate</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>UR-63325</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone propionate nasal spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UR-63325</intervention_name>
    <description>UR-63325</description>
    <arm_group_label>UR-63325</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone propionate nasal spray</intervention_name>
    <description>Fluticasone propionate nasal spray</description>
    <arm_group_label>Fluticasone propionate nasal spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to UR 63325 and fluticasone propionate nasal spray</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written informed consent to participate (prior to any study-related
             procedures being performed) as shown by a signature on the volunteer consent form and
             to be able to adhere to the study restrictions and examination schedule

          -  Subjects with confirmed history of seasonal allergic rhinitis to grass pollen (by
             direct questioning of presence of positive skin prick test to pollen and History of
             Symptoms of allergic rhinitis) within the previous two years

          -  Positive skin prick test to timothy grass pollen (wheal difference with negative
             control ≥ 3 mm) at screening

          -  Subjects with positive response to screening nasal challenge with increasing doses of
             timothy grass pollen (Symptoms worsening with respect to the response to the diluent
             challenge of ≥4 points in the total nasal symptom score [TNSS]) within one hour after
             last nasal allergen challenge

          -  Screening and baseline FEV1 &gt;80% predicted and FEV1/FVC &gt; 70% predicted

        Exclusion Criteria:

          -  Symptoms of allergic rhinitis within 2 weeks prior to screening

          -  Upper respiratory infection or sinusitis within 14 days of screening and also within
             14 days of study start in each of the two periods

          -  Structural nasal abnormalities or nasal polyps on examination, a history of nose
             bleeding or recent nasal surgery

          -  History of asthma or asthmatic symptoms or other respiratory disease other than
             rhinitis within the last 2 years or FEV1&lt;80% of predicted at screening or baseline
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainard Fuhr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel International GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2010</study_first_submitted>
  <study_first_submitted_qc>December 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2010</study_first_posted>
  <last_update_submitted>April 14, 2011</last_update_submitted>
  <last_update_submitted_qc>April 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Roser Vives MD, Clinical Research Scientist</name_title>
    <organization>Palau Pharma S.A.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

